Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
57469-77-9
Molecular formula
C19H32N2O4
Molecular weight
352.5 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)propionic-acid derivative
Mechanism of action
Reversibly inhibits cyclo-oxygenase-1 and cyclo-oxygenase-2, reducing prostaglandin synthesis and producing analgesic, antipyretic and anti-inflammatory effects. Arginine and lysine are counter-ions in particular salt formulations and do not create a different ibuprofen pharmacological target.
Indications / reported uses
Symptomatic relief of mild-to-moderate pain and fever
Treatment of inflammatory and painful conditions including osteoarthritis, rheumatoid arthritis, dysmenorrhoea and musculoskeletal pain
Paediatric fever and pain relief with age- and formulation-appropriate products; product-specific indications and dose limits apply
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Ibuprofen Lysine Environmental Risk Assessment (ERA) (the Ibuprofen Lysine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.